1. A strategy for the development of two clinically active cisplatin analogs: CBDCA and CHIP.
- Author
-
Foster, Brenda, Harding, Bonnie, Wolpert-DeFilippes, Mary, Rubinstein, Lawrence, Clagett-Carr, Kathleen, Leyland-Jones, Brian, Foster, B J, Harding, B J, Wolpert-DeFilippes, M K, Rubinstein, L Y, Clagett-Carr, K, and Leyland-Jones, B
- Subjects
LEUKEMIA ,CANCER chemotherapy ,ANTINEOPLASTIC agents ,CHEMISTRY ,CISPLATIN ,CLINICAL drug trials ,MOLECULAR structure ,ORGANOPLATINUM compounds ,TUMORS ,DRUG development ,CARBOPLATIN ,PHARMACODYNAMICS ,THERAPEUTICS - Abstract
The antitumor agent cisplatin has a broad antitumor spectrum and has been incorporated into regimens that are curative for some malignant diseases. However, one of the major limitations to its clinical usefulness is the incidence of severe toxicities involving several major organ systems. Therefore, much enthusiasm has been generated for the development of cisplatin analogs that demonstrate an improved therapeutic index in some preclinical models. The two most promising analogs are CBDCA (carboplatin) and CHIP (iproplatin). The preclinical and early clinical trial results have demonstrated that these two compounds show activity in cisplatin-responsive tumors. The preclinical background providing the rationale for the clinical development of these two analogs is described. We suggest a means of screening for each analog's clinical antitumor activity and determining the analogs' utility against specific malignant diseases compared with that of the parent compound or standard treatment. [ABSTRACT FROM AUTHOR]
- Published
- 1990
- Full Text
- View/download PDF